Evidence map›Paper›PMID 34638284›Full record

ArticleCancers2021

Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression.

Barbora Zwinsová, Vyacheslav A Petrov, Martina Hrivňáková, Stanislav Smatana, Lenka Micenková, Natálie Kazdová, Vlad Popovici, Roman Hrstka, Roman Šefr, Beatrix Bencsiková and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. CombiningFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Barbora ZwinsováResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.ORCID 0000-0002-3481-3232
Vyacheslav A PetrovResearch Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
Martina HrivňákováResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Stanislav SmatanaResearch Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
Lenka MicenkováResearch Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
Natálie KazdováResearch Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
Vlad PopoviciResearch Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
Roman HrstkaResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.ORCID 0000-0002-6139-2664
Roman ŠefrResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Beatrix BencsikováResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Lenka Zdražilová-DubskáDepartment of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.ORCID 0000-0001-6397-0993
Veronika BrychtováResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Rudolf NenutilResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Petra VídeňskáResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Eva BudinskáResearch Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
Masaryk University · CZMasaryk Memorial Cancer Institute · CZ

Funding

Horizon 2020 Framework Programme 825410Ministerstvo Zdravotnictví Ceské Republiky AZV 16-31966A
6 · The paper itself

Abstract

Long-term dysbiosis of the gut microbiome has a significant impact on colorectal cancer (CRC) progression and explains part of the observed heterogeneity of the disease. Even though the shifts in gut microbiome in the normal-adenoma-carcinoma sequence were described, the landscape of the microbiome within CRC and its associations with clinical variables remain under-explored. We performed 16S rRNA gene sequencing of paired tumour tissue, adjacent visually normal mucosa and stool swabs of 178 patients with stage 0-IV CRC to describe the tumour microbiome and its association with clinical variables. We identified new genera associated either with CRC tumour mucosa or CRC in general. The tumour mucosa was dominated by genera belonging to oral pathogens. Based on the tumour microbiome, we stratified CRC patients into three subtypes, significantly associated with prognostic factors such as tumour grade, sidedness and TNM staging,

Indexed as

16S rRNA genecolorectal cancermicrobial subtypestumour microbiome

Identifiers

PMID34638284
PMCPMC8507728
OpenAlexW3202688589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.